PX 12
Alternative Names: IV 2 compound; IV-2; PX-12; thioredoxin inhibitor PX-12; thioredoxin-1 inhibitor PX-12Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator University of Arizona
- Developer National Cancer Institute (USA); Oncothyreon; ProlX Pharmaceuticals; Translational Genomics Research Institute
- Class Antineoplastics; Disulfides; Imidazoles; Small molecules
- Mechanism of Action Thioredoxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer; Gastrointestinal cancer; Pancreatic cancer
Most Recent Events
- 11 Jun 2008 Phase-Ib clinical trials in advanced or metastatic Cancer in USA (IV)
- 16 Apr 2008 Pharmacodynamics data from phase I trials in Cancer presented at the 99th Annual Meeting of the American Association for Cancer Research (AACR-2008)
- 30 Jan 2008 PX 12 is still in phase II trials for advanced Pancreatic cancer in the USA (IV)